Previsioni

Il prezzo obiettivo medio degli analisti è +12,02€ (+169,51%). La mediana è +11,16€ (+150,22%).

Acquista	24
Mantieni	1
Vendi	0

Notizie Vai al feed delle notizie

Wave Life Sciences unveils RNA pipeline and secures funding through Q3 2028

Wave Life Sciences highlights its proprietary chemistry platform as the core strategy and is concentrating capital on three lead candidates: WVE-007 (obesity), WVE-006 (alpha-1 antitrypsin deficiency) and WVE-008 (PNPLA3-associated liver disease). The company has about $500 million in cash, sufficient through the third quarter of 2028, and expects multiple clinical data readouts and regulatory feedback over the next 12–18 months. Early-stage data for WVE-007 showed fat reduction with muscle preservation and for WVE-006 showed consistent RNA-editing activity; WVE-008 is planned to start clinical testing in H2 2024. Management views WVE-007 as complementary to GLP-1 therapies and is exploring partnerships but intends to present additional data first. » Altro su de.investing.com
Wave Life Sciences relocates headquarters to Delaware and continues Nasdaq trading under ticker WVE

Wave Life Sciences has completed the relocation of its legal domicile from Singapore to Delaware; the new parent company is Wave Life Sciences, Inc., with a 1:1 share exchange that made the former Wave Life Sciences Ltd. a 100% subsidiary. The old shares of the Singapore entity will be suspended and delisted from the Nasdaq Global Market before trading opens on Monday, and the new common shares of the Delaware company will be traded from Monday under the same ticker WVE; the company also plans to file a Form 15 to terminate the former entity’s registration. Ongoing equity compensation programs, the board and executives were carried over and the charter was redrafted in Delaware; additional classes of shares will not be listed on the exchange. » Altro su de.investing.com
Wave Life Sciences relocates headquarters from Singapore to the US and converts parent company into a Delaware corp.

Wave Life Sciences said the relocation of its headquarters from Singapore to the US is expected to become effective on Friday after market close. Shareholders approved the move and the High Court of Singapore had already approved the restructuring on 14 July 2026. Implementation will be effected by filing the court order with the Singapore regulator; the company then plans to file documents with the US SEC and convert the parent company into a corporation formed under Delaware law. Wave conducts research on RNA therapies for obesity, alpha-1 antitrypsin deficiency and liver diseases, and runs clinical programs for Duchenne muscular dystrophy and Huntington’s chorea. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, WAVE Life Sciences ha registrato ricavi pari a 1,99M€ e un utile netto di −60,77M€

(EUR)	giu 2026	YoY
Ricavi	+1,99M	73,03%
Utile lordo	+1,99M	63,92%
Utile netto	−60,77M	41,92%
EBITDA	−62,40M	52,37%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+866,03M€
Numero di azioni	197,05M
Massimo/minimo a 52 settimane	+18,65€ - +4,30€
Dividendi	No
Beta	-1,29
Rapporto P/E	−4,70
Rapporto PEG	+0,09
Rapporto P/B	+2,28
Rapporto P/S	+15,43

Profilo aziendale

Wave Life Sciences Ltd., ein Unternehmen für genetische Medizin in der klinischen Phase, entwirft, optimiert und produziert neuartige stereoreine Oligonukleotide mit Hilfe von PRISM, einer Plattform für die Entdeckung und Entwicklung von Medikamenten. Das Unternehmen entwickelt Oligonukleotide, die auf Ribonukleinsäure abzielen, um die Expression von krankheitsfördernden Proteinen zu reduzieren, die Produktion von funktionellen Proteinen wiederherzustellen oder die Proteinexpression zu modulieren. Das Unternehmen entwickelt auch WVE-004, ein C9orf72-Molekül zur Behandlung von amyotropher Lateralsklerose und frontotemporaler Demenz; WVE-003, ein SNP3-Molekül zur Behandlung der Huntington-Krankheit; WVE-N531, ein Exon 53-Molekül zur Behandlung der Duchenne-Muskeldystrophie, und ATXN3, ein Forschungsprogramm zur Behandlung der spinozerebellären Ataxie 3, sowie mehrere präklinische Programme für ZNS-Erkrankungen. Darüber hinaus konzentriert sich das Unternehmen auf die Entwicklung von GalNAc-konjugierten AIMern zur Behandlung von Leberindikationen, die den Alpha-1-Antitrypsin-Mangel (AATD) umfassen, sowie auf zwei präklinische Programme, wie das Usher-Syndrom Typ 2A (USH2A) und Retinitis pigmentosa aufgrund einer P23H-Mutation im RHO-Gen (RhoP23H) zur Behandlung von Netzhauterkrankungen. Das Unternehmen hat Kooperationsvereinbarungen mit Pfizer Inc. und Takeda Pharmaceutical Company Limited, der University of Oxford, der University of Massachusetts, der Western Washington University, dem Grenoble Institute of Neurosciences, IRBM S.p.A, der University of Louisville und dem University College London. Das Unternehmen wurde im Jahr 2012 gegründet und hat seinen Sitz in Singapur.

Nome	WAVE Life Sciences
CEO	Paul Bolno
Sede centrale	Cambridge, ma Singapore
Sito web	wavelifesciences.com
Settore	Materiali
Industria	Prodotti chimici
Quotazione in borsa	11/11/2015
Dipendenti	317